LIFE, US0021202025

aTyr Pharma stock heads into November 5 earnings at USD 18.9 million value

Published on 10/15/2026 at 20:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter earnings per share came to USD -0.11 on June 30, 2026. aTyr Pharma stock costs EUR 0.17 on October 15, 2026 at 8:42 p.m. CEST.

Earnings date and valuation

aTyr Pharma is expected to report earnings on November 5, 2026.
Second-quarter earnings per share came to USD -0.11 on June 30, 2026.
aTyr Pharma stock costs EUR 0.17 at Lang & Schwarz on October 15, 2026 at 8:42 p.m. CEST.
aTyr Pharma had a market capitalization of USD 18.9 million on October 15, 2026.

LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma (ISIN US0021202025) is expected to report its next earnings on November 5, 2026, according to Zacks. The scheduled date gives the biotechnology company its next clear calendar marker. At Lang & Schwarz, the stock stood at EUR 0.17 on October 15, 2026 at 8:42 p.m. CEST.

Second-quarter earnings context

MarketBeat reported second-quarter 2026 earnings per share of USD -0.11 on August 7, 2026, compared with a consensus estimate of USD -0.12. The USD 0.01 difference was a quantified improvement against expectations, while the company remained loss-making in the period. Standardized financial data put consolidated net income at USD -10.31 million for the quarter ended June 30, 2026.

Price position on Nasdaq

Investing.com identifies aTyr Pharma as a Nasdaq-listed company trading under ATYR. The home-market quote was last at USD 0.19 on October 15, 2026 at 2:52 p.m. ET. Its 52-week range was USD 0.18 to USD 1.11, putting the latest home-market price USD 0.01 above the annual low and USD 0.92 below the annual high.

The Nasdaq quote carried a market capitalization of USD 18.9 million on October 15, 2026. Trading volume reached 1,693,186 shares against an average of 3,221,662 shares, while the price-to-earnings ratio was negative 0.31 and the trailing dividend yield was 0.00 percent.

Valuation and November 5

The upcoming November 5 reporting date matters because the next release can update the earnings picture after the USD -0.11 second-quarter result. The current valuation also reflects a small-cap biotechnology profile: market capitalization remained below USD 20.0 million, and the annual price range stretched from USD 0.18 to USD 1.11.

Comparison with peers

aTyr Pharma: price-to-earnings ratio -0.31, market capitalization USD 18.9 million
Jasper Therapeutics (Nasdaq, USD): daily change 6.37 percent, price-to-earnings ratio -0.34, market capitalization USD 17.7 million
FibroGen (Nasdaq, USD): daily change minus 1.63 percent, price-to-earnings ratio 0.20, market capitalization USD 36.7 million

Investor calendar

The next scheduled earnings date is November 5, 2026, according to Zacks. The release is expected to cover the quarter ending September 2026.

Euro price at Lang & Schwarz

The euro quotation stood at EUR 0.17 at Lang & Schwarz on October 15, 2026 at 8:42 p.m. CEST. The separate Nasdaq quotation was USD 0.19 at 2:52 p.m. ET on the same date.

The further course of trading is shown by the continuously updated real-time quote of aTyr Pharma stock.